Drugs / Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted)
Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06842173 | Sep 2025 → Aug 2027 expected | avian influenza | Butantan Institute | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Monovalent Influenza Vaccine A (H5N8) (Inactivated, Fragmented, and Adjuvanted) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06842173 ↗ |
| Modality | Vaccine | “monovalent influenza vaccine candidate A (H5N8) (inactivated, fragmented, and adjuvanted with IB160)” NCT06842173 ↗ |